Not available
Quote | BeiGene Ltd. (NASDAQ:BGNE)
Last: | $178.50 |
---|---|
Change Percent: | -0.62% |
Open: | $180.99 |
Close: | $178.50 |
High: | $181.78 |
Low: | $177.93 |
Volume: | 137,848 |
Last Trade Date Time: | 10/02/2023 03:00:00 am |
News | BeiGene Ltd. (NASDAQ:BGNE)
2023-09-24 22:33:00 ET Summary Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene...
2023-09-19 06:58:00 ET More on BeiGene, Novartis, etc. Sales Success Comes With Side Effects For Drug Maker BeiGene Novartis: Q2 Beats Expectations, But Still Pricey Novartis: Strong Growth And Continued Expansion For KISQALI Novartis shareholders approve 100...
Message Board Posts | BeiGene Ltd. (NASDAQ:BGNE)
Subject | By | Source | When |
---|---|---|---|
BGNE having a nice bounce and a good, | MiamiGent | investorshub | 07/05/2023 7:28:03 PM |
Thoughts on where this is headed? | StockLearner2011 | investorshub | 07/03/2023 9:49:33 PM |
Found an interesting article | luke424 | investorshub | 06/30/2023 1:45:08 AM |
$BGNE must see | StockLearner2011 | investorshub | 06/28/2023 1:49:55 AM |
here we go bulls news is here | StockLearner2011 | investorshub | 06/22/2023 3:12:55 PM |
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. Digital Transformation Opportunities Corp. (NASDAQ: DTOC) rose 100.7% t...
Bloomberg Amazon Poaches Microsoft's Product Chief Ahead Of Its Annual Devices Event After Microsoft Corp (NASDAQ: MSFT) Chief Produ...
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, fr...